Antisense oligonucleotide based therapeutics and its applications against bacterial infections

Bennett, 2019, Therapeutic antisense oligonucleotides are coming of age, Annu Rev Med, 70, 307, 10.1146/annurev-med-041217-010829 Woodford, 2009, Tackling antibiotic resistance: a dose of common anti sense?, J Antimicrob Chemother, 63, 225, 10.1093/jac/dkn467 Shen, 2018, Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs, Nucleic Acids Res, 46, 1584, 10.1093/nar/gkx1239 Weiss, 1999, Antisense RNA gene therapy for studying and modulating biological processes, Cell Mol Life Sci, 55, 334, 10.1007/s000180050296 Chery, 2016, RNA therapeutics: RNAi and antisense mechanisms and clinical applications, Postdoc journal: a journal of postdoctoral research and postdoctoral affairs, 4, 35, 10.14304/SURYA.JPR.V4N7.5 Mansoor, 2008, Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics, Gene regulation and systems biology, 2, GRSB-S418, 10.4137/GRSB.S418 Agrawal, 2010, Remembering Paul C. Zamecnik, MD, Father of Antisense (1912–2009), Oligonucleotides, 20, 47, 10.1089/oli.2009.2001.obz Zamecnik, 1978, Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide, Proceedings of the National Academy of Sciences, 75, 280, 10.1073/pnas.75.1.280 Stephenson, 1978, Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide, Proceedings of the National Academy of Sciences, 75, 285, 10.1073/pnas.75.1.285 Paterson, 1977, Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation, Proceedings of the National Academy of Sciences, 74, 4370, 10.1073/pnas.74.10.4370 Karaki, 2019, Antisense Oligonucleotides, A Novel Developing Targeting Therapy, Antisense Therapy, 10, 10.5772/intechopen.82105 Wan, 2016, The medicinal chemistry of therapeutic oligonucleotides, J Med Chem, 59, 9645, 10.1021/acs.jmedchem.6b00551 Dowdy, 2017, Overcoming cellular barriers for RNA therapeutics, Nat Biotechnol, 35, 222, 10.1038/nbt.3802 Uhlmann, 1990, Antisense oligonucleotides: a new therapeutic principle, Chem Rev, 90, 543, 10.1021/cr00102a001 Sharma, 2014, Antisense oligonucleotides: modifications and clinical trials, MedChemComm, 5, 1454, 10.1039/C4MD00184B Micklefield, 2001, Backbone modification of nucleic acids: synthesis, structure and therapeutic applications, Curr Med Chem, 8, 1157, 10.2174/0929867013372391 Matsukura, 1987, Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus, Proc Natl Acad Sci, 84, 7706, 10.1073/pnas.84.21.7706 Jahns, 2022, Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo, Nucleic Acids Res, 50, 1221, 10.1093/nar/gkab544 Miyake, 2008, Negative regulation by SHPS-1 of Toll-like receptor-dependent proinflammatory cytokine production in macrophages, Genes Cells, 13, 209, 10.1111/j.1365-2443.2007.01161.x Winkler, 2010, Off-target effects related to the phosphorothioate modification of nucleic acids, ChemMedChem, 5, 1344, 10.1002/cmdc.201000156 Liang, 2015, Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages, Nucleic Acids Res, 43, 2927, 10.1093/nar/gkv143 Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.American journal of ophthalmology 2002; 133(4): 467-474. Crooke, 2013, Clinical pharmacological properties of mipomersen (Kynamro), a second-generation antisense inhibitor of apolipoprotein B, Br J Clin Pharmacol, 76, 269, 10.1111/j.1365-2125.2012.04469.x Aartsma-Rus, 2017, FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides, Nucleic Acid Ther, 27, 67, 10.1089/nat.2017.0665 Finkel, 2016, Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study, Lancet, 388, 3017, 10.1016/S0140-6736(16)31408-8 Eteplirsen briefing document NDA 206488. Cambridge, MA: Sarepta Therapeutics, January 22, 2016 https://www.fda.gov/downloads/advisory committees/ committees meeting materials/drugs/ peripheral and central nervous system drugs advisory committee /ucm481912.pdf. Benson, 2018, Inotersen treatment for patients with hereditary transthyretin amyloidosis, N Engl J Med, 379, 22, 10.1056/NEJMoa1716793 Mathew, 2019, Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis, Drug Des Devel Ther, 1515, 10.2147/DDDT.S162913 Heo, 2020, Golodirsen: first approval, Drugs, 80, 329, 10.1007/s40265-020-01267-2 Witztum, 2019, Volanesorsen and triglyceride levels in familial chylomicronemia syndrome, N Engl J Med, 381, 531, 10.1056/NEJMoa1715944 Kim, 2019, Patient-customized oligonucleotide therapy for a rare genetic disease, N Engl J Med, 381, 1644, 10.1056/NEJMoa1813279 Ng, 2006, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat Rev Drug Discov, 5, 123, 10.1038/nrd1955 Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration, N Engl J Med, 351, 2805, 10.1056/NEJMoa042760 FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation, February 25, 2021 (https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation). Shirley, 2021, Casimersen: first approval, Drugs, 81, 875, 10.1007/s40265-021-01512-2 Agris, 1986, Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates, Biochemistry, 25, 6268, 10.1021/bi00368a065 Agrawal, 1988, Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus, Proc Natl Acad Sci, 85, 7079, 10.1073/pnas.85.19.7079 Ozawa, 2004, Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts, Neuro Oncol, 6, 218, 10.1215/S1152851704000055 Wang, 2004, Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma, Blood, 103, 258, 10.1182/blood-2003-02-0546 Gryaznov, 1995, Oligonucleotide N3'–> P5'phosphoramidates, Proc Natl Acad Sci, 92, 5798, 10.1073/pnas.92.13.5798 Gryaznov, 1996, Oligonucleotide N3′→ P5′ phosphoramidates as antisense agents, Nucleic Acids Res, 24, 1508, 10.1093/nar/24.8.1508 Sanghvi, 1997, Concept, discovery and development of MMI linkage: story of a novel linkage: for antisense constructs, Nucleosides Nucleotides Nucleic Acids, 16, 907, 10.1080/07328319708006107 Peoc'h, 2004, Synthesis of 2′-Substituted MMI Linked Nucleosidic Dimers: An Optimization Study in Search of High Affinity Oligonucleotides for Use in Antisense Constructs, Nucleosides Nucleotides Nucleic Acids, 23, 411, 10.1081/NCN-120028337 Yang, 1999, NMR Structure of an Antisense DNA⊙ RNA Hybrid Duplex Containing a 3 ‘-CH2N (CH3)-O-5 ‘or an MMI Backbone Linker, Biochemistry, 38, 12586, 10.1021/bi990456x Zhang, 1999, Synthesis and hybridization property of an oligonucleotide containing a 3′-thioformcetal linked pentathymidylate, Bioorg Med Chem Lett, 9, 319, 10.1016/S0960-894X(98)00741-0 Cross, 1997, Solution Structure of an RNA⊙ DNA Hybrid Duplex Containing a 3 ‘-Thioformacetal Linker and an RNA A-Tract, Biochemistry, 36, 4096, 10.1021/bi962382k Jones, 1993, Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements: the formacetal and 3'-thioformacetal internucleoside linkages, J Org Chem, 58, 2983, 10.1021/jo00063a014 He, 1998, In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages, J Med Chem, 41, 4224, 10.1021/jm970766i Altmann, 1996, Second-generation antisense oligonucleotides: Structure—Activity relationships and the design of improved signal-transduction inhibitors, Biochem Soc Trans, 24, 630, 10.1042/bst0240630 Monia, 1993, Evaluation of 2 ‘-modified oligonucleotides containing 2 ‘-deoxy gaps as antisense inhibitors of gene expression, J Biol Chem, 268, 14514, 10.1016/S0021-9258(19)85268-7 Pattanayek, 2004, Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2 ‘-O-modified nucleic acid analogues, J Am Chem Soc, 126, 15006, 10.1021/ja044637k Egholm, 1992, Peptide nucleic acids (PNA). Oligonucleotide analogs with an achiral peptide backbone, J Am Chem Soc, 114, 1895, 10.1021/ja00031a062 Nielsen, 1999, An introduction to peptide nucleic acid, Curr Issues Mol Biol, 1, 89 Koppelhus, 2003, Cellular delivery of peptide nucleic acid (PNA), Adv Drug Deliv Rev, 55, 267, 10.1016/S0169-409X(02)00182-5 Pellestor, 2008, Peptide nucleic acids (PNAs) as diagnostic devices for genetic and cytogenetic analysis, Curr Pharm Des, 14, 2439, 10.2174/138161208785777405 Paulasova, 2004, The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses, Ann Genet, 47, 349, 10.1016/j.anngen.2004.07.001 Bhandari, 2014, Antisense oligonucleotide: basic concept and its therapeutic application, Proteins, 9, 10 Braasch, 2001, Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA, Chem Biol, 8, 1, 10.1016/S1074-5521(00)00058-2 Bondensgaard, 2000, Structural studies of LNA: RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry–A, European Journal, 6, 2687, 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.0.CO;2-U Eichert, 2010, The crystal structure of an ‘All Locked’nucleic acid duplex, Nucleic Acids Res, 38, 6729, 10.1093/nar/gkq505 Vester, 2004, LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA, Biochemistry, 43, 10.1021/bi0485732 Kurreck, 2002, Design of antisense oligonucleotides stabilized by locked nucleic acids, Nucleic Acids Res, 30, 1911, 10.1093/nar/30.9.1911 Wahlestedt, 2000, Potent and nontoxic antisense oligonucleotides containing locked nucleic acids, Proc Natl Acad Sci, 97, 5633, 10.1073/pnas.97.10.5633 Seth, 2009, Short antisense oligonucleotides with novel 2′− 4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals, J Med Chem, 52, 10, 10.1021/jm801294h Petersen, 2003, LNA: a versatile tool for therapeutics and genomics, Trends Biotechnol, 21, 74, 10.1016/S0167-7799(02)00038-0 Jepsen, 2004, Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology, Oligonucleotides, 14, 130, 10.1089/1545457041526317 Summerton JE, Weller DD. Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages. U.S. Patent 5,185,444. 1993. Nelson, 2005, Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity, Bioconjug Chem, 16, 959, 10.1021/bc0501045 McCaffrey, 2003, A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice, Hepatology, 38, 503, 10.1053/jhep.2003.50330 Iversen, 2003, Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans, Clin Cancer Res, 9, 2510 Kipshidze, 2002, Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model, J Am Coll Cardiol, 39, 1686, 10.1016/S0735-1097(02)01830-2 Moulton, 2009, Gene knockdowns in adult animals: PPMOs and vivo-morpholinos, Molecules, 14, 1304, 10.3390/molecules14031304 Cerritelli, 2009, Ribonuclease H: the enzymes in eukaryotes, FEBS J, 276, 1494, 10.1111/j.1742-4658.2009.06908.x Lima, 2016, Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function, Nucleic Acids Res, 44, 5299, 10.1093/nar/gkw350 Crooke, 2017, Molecular mechanisms of antisense oligonucleotides, Nucleic Acid Ther, 27, 70, 10.1089/nat.2016.0656 Vickers, 2014, Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms, PLoS One, 9, 10, 10.1371/journal.pone.0108625 Vickers, 2015, The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA, Nucleic Acids Res, 43, 8955, 10.1093/nar/gkv920 Dias, 2002, Antisense oligonucleotides: basic concepts and mechanisms, Mol Cancer Ther, 1, 347 Sharp, 2009, The centrality of RNA, Cell, 136, 577, 10.1016/j.cell.2009.02.007 Crooke, 2000, Progress in antisense technology: the end of the beginning, Methods Enzymol, 313, 3, 10.1016/S0076-6879(00)13003-4 Svasti, 2009, RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice, Proc Natl Acad Sci, 106, 1205, 10.1073/pnas.0812436106 Hua, 2011, Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model, Nature, 478, 123, 10.1038/nature10485 Hua, 2010, Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes Dev, 24, 1634, 10.1101/gad.1941310 Passini, 2011, Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy, Sci Transl Med, 3, 10.1126/scitranslmed.3001777 Lu, 2005, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles, Proc Natl Acad Sci, 102, 198, 10.1073/pnas.0406700102 Havens, 2016, Splice-switching antisense oligonucleotides as therapeutic drugs, Nucleic Acids Res, 44, 6549, 10.1093/nar/gkw533 Cowsert, 1993, In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts, Antimicrob Agents Chemother, 37, 171, 10.1128/AAC.37.2.171 Crooke, 1999, Molecular mechanisms of action of antisense drugs, Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1489, 31, 10.1016/S0167-4781(99)00148-7 Baker, 1992, Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides, J Biol Chem, 267, 11495, 10.1016/S0021-9258(19)49937-7 Juliano, 2016, The delivery of therapeutic oligonucleotides, Nucleic Acids Res, 44, 6518, 10.1093/nar/gkw236 Komarova, 2010, Regulation of endothelial permeability via paracellular and transcellular transport pathways, Annu Rev Physiol, 72, 463, 10.1146/annurev-physiol-021909-135833 Tarbell, 2010, Shear stress and the endothelial transport barrier, Cardiovasc Res, 87, 320, 10.1093/cvr/cvq146 Hammond, 2021, Delivery of oligonucleotide-based therapeutics: challenges and opportunities, EMBO Mol Med, 13, e13243, 10.15252/emmm.202013243 Roberts, 2020, Advances in oligonucleotide drug delivery, Nat Rev Drug Discov, 19, 673, 10.1038/s41573-020-0075-7 Ezzat, 2015, Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides, Nano Lett, 15, 4364, 10.1021/acs.nanolett.5b00490 Benimetskaya, 1997, Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein, Nat Med, 3, 414, 10.1038/nm0497-414 Butler, 2000, Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice, J Pharmacol Exp Ther, 292, 489 Haraldsson, 2008, Properties of the glomerular barrier and mechanisms of proteinuria, Physiol Rev, 10.1152/physrev.00055.2006 Geary, 2015, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides, Adv Drug Deliv Rev, 87, 46, 10.1016/j.addr.2015.01.008 Geary, 2009, Antisense oligonucleotide pharmacokinetics and metabolism, Expert Opin Drug Metab Toxicol, 5, 381, 10.1517/17425250902877680 Dirin, 2013, Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides, Expert Opin Biol Ther, 13, 875, 10.1517/14712598.2013.774366 Southwell, 2012, Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases, Trends Mol Med, 18, 634, 10.1016/j.molmed.2012.09.001 Hayek, 2011, Intrathecal therapy for cancer and non-cancer pain, Pain Physician, 14, 219, 10.36076/ppj.2011/14/219 Kordasiewicz, 2012, Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis, Neuron, 74, 1031, 10.1016/j.neuron.2012.05.009 Kalbfuss, 2001, Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17, J Biol Chem, 276, 42986, 10.1074/jbc.M105113200 Chauhan, 2007, Antisense inhibition at the β-secretase-site of β-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576, Neuroscience, 146, 143, 10.1016/j.neuroscience.2007.01.008 Williams, 2009, Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy, J Neurosci, 29, 7633, 10.1523/JNEUROSCI.0950-09.2009 Smith, 2006, Antisense oligonucleotide therapy for neurodegenerative disease, J Clin Invest, 116, 2290, 10.1172/JCI25424 Evers, 2015, Antisense oligonucleotides in therapy for neurodegenerative disorders, Adv Drug Deliv Rev, 87, 90, 10.1016/j.addr.2015.03.008 Healy, 2004, Pharmacokinetics and biodistribution of novel aptamer compositions, Pharm Res, 21, 2234, 10.1007/s11095-004-7676-4 Burcovich, 1998, Branched polyethylene glycol (bPEG) conjugated antisense oligonucleotides, Nucleosides Nucleotides, 17, 1567, 10.1080/07328319808004687 Winkler, 2013, Oligonucleotide conjugates for therapeutic applications, Ther Deliv, 4, 791, 10.4155/tde.13.47 Hagiwara, 2018, PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect, J Biomater Sci Polym Ed, 29, 448, 10.1080/09205063.2017.1422853 Manoharan, 2002, Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action, Antisense Nucleic Acid Drug Dev, 12, 103, 10.1089/108729002760070849 Wang, 2019, Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells, Nucleic Acid Ther, 29, 245, 10.1089/nat.2019.0794 Prakash, 2019, Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle, Nucleic Acids Res, 47, 6029, 10.1093/nar/gkz354 McClorey, 2018, Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics, Biomedicines, 6, 51, 10.3390/biomedicines6020051 Nagahara, 1998, Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration, Nat Med, 4, 1449, 10.1038/4042 Qian, 2015, Monitoring the cytosolic entry of cell-penetrating peptides using a pH-sensitive fluorophore, Chemical Communications, 51, 2162, 10.1039/C4CC09441G Lindgren, 2006, Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide, Biochem Pharmacol, 71, 416, 10.1016/j.bcp.2005.10.048 Zhang, 2013, A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system, Biomaterials, 34, 7980, 10.1016/j.biomaterials.2013.07.014 Khafagy, 2012, Oral biodrug delivery using cell-penetrating peptide, Adv Drug Deliv Rev, 64, 531, 10.1016/j.addr.2011.12.014 Tyagi, 2001, Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans, J Biol Chem, 276, 3254, 10.1074/jbc.M006701200 Nakase, 2007, Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis, Biochemistry, 46, 492, 10.1021/bi0612824 Fittipaldi, 2003, Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins, J Biol Chem, 278, 34141, 10.1074/jbc.M303045200 Gestin M, Dowaidar M. and Langel U. Uptake mechanism of cell-penetrating peptides.Peptides and peptide-based biomaterials and their biomedical applications. Springer, Cham, 2017. Pp. 255-264. Cleal K, He L, D Watson P, & T Jones A. Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles.Current pharmaceutical design 2013; 19(16): 2878-2894. Boisguérin, 2015, Delivery of therapeutic oligonucleotides with cell penetrating peptides, Adv Drug Deliv Rev, 87, 52, 10.1016/j.addr.2015.02.008 Foged, 2008, Cell-penetrating peptides for drug delivery across membrane barriers, Expert Opin Drug Deliv, 5, 105, 10.1517/17425247.5.1.105 Sazani, 2002, Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat Biotechnol, 20, 1228, 10.1038/nbt759 Bendifallah, 2006, Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA), Bioconjug Chem, 17, 750, 10.1021/bc050283q Boffa, 2007, Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc, Cancer Gene Ther, 14, 220, 10.1038/sj.cgt.7701002 Fabani, 2010, Efficient inhibition of miR-155 function in vivo by peptide nucleic acids, Nucleic Acids Res, 38, 4466, 10.1093/nar/gkq160 Amantana, 2007, Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide− morpholino oligomer conjugate, Bioconjug Chem, 18, 1325, 10.1021/bc070060v Yin, 2008, Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function, Hum Mol Genet, 17, 3909, 10.1093/hmg/ddn293 Wu, 2008, Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer, Proc Natl Acad Sci, 105, 14814, 10.1073/pnas.0805676105 Goyenvalle, 2015, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat Med, 21, 270, 10.1038/nm.3765 Leger, 2013, Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy, Nucleic Acid Ther, 23, 109, 10.1089/nat.2012.0404 Echigoya, 2017, Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy, Proc Natl Acad Sci, 114, 4213, 10.1073/pnas.1613203114 Yin, 2011, Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice, Mol Ther, 19, 1295, 10.1038/mt.2011.79 Kurrikoff, 2021, Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics, Expert Opin Biol Ther, 21, 361, 10.1080/14712598.2021.1823368 Du, 2011, Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum, Hum Mol Genet, 20, 3151, 10.1093/hmg/ddr217 Shabanpoor, 2017, Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy, Nucleic Acid Ther, 27, 130, 10.1089/nat.2016.0652 Mercuri, 2018, Nusinersen versus sham control in later-onset spinal muscular atrophy, N Engl J Med, 378, 625, 10.1056/NEJMoa1710504 Finkel, 2017, Nusinersen versus sham control in infantile-onset spinal muscular atrophy, N Engl J Med, 377, 1723, 10.1056/NEJMoa1702752 Lai, 2008, Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice, Mol Ther, 16, 1120, 10.1038/mt.2008.81 Opriessnig, 2011, Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptide-conjugated morpholino oligomer, Antiviral Res, 91, 36, 10.1016/j.antiviral.2011.04.012 Burrer, 2007, Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models, J Virol, 81, 5637, 10.1128/JVI.02360-06 Warren, 2012, Advanced morpholino oligomers: a novel approach to antiviral therapy, Antiviral Res, 94, 80, 10.1016/j.antiviral.2012.02.004 Debacker, 2020, Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug, Mol Ther, 28, 1759, 10.1016/j.ymthe.2020.06.015 Tanowitz, 2017, Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes, Nucleic Acids Res, 45, 12388, 10.1093/nar/gkx960 Prakash, 2014, Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice, Nucleic Acids Res, 42, 8796, 10.1093/nar/gku531 Prakash, 2018, Evaluation of the effect of 2′-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice, Bioorg Med Chem Lett, 28, 3774, 10.1016/j.bmcl.2018.10.011 Crooke, 2019, Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides: I, Human volunteer experience nucleic acid therapeutics, 29, 16, 10.1089/nat.2018.0753 Wang, 2019, Pharmacokinetics and clinical pharmacology considerations of GalNAc3-conjugated antisense oligonucleotides, Expert Opin Drug Metab Toxicol, 15, 475, 10.1080/17425255.2019.1621838 Yu, 2016, Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys, Nucleic Acid Ther, 26, 372, 10.1089/nat.2016.0623 Viney, 2016, Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): two randomised, double-blind, placebo-controlled, dose-ranging trials, Lancet, 388, 2239, 10.1016/S0140-6736(16)31009-1 Tsimikas, 2020, Lipoprotein (a) reduction in persons with cardiovascular disease, N Engl J Med, 382, 244, 10.1056/NEJMoa1905239 Novartis to pursue transformational therapy to reduce risk of car- diovascular disease in people living with elevated levels of inherited lipoprotein(a), Feb 25, 2019. https://www.novartis.com/news/media-releases/novartis-pursue-transformational- therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina. Ämmälä, 2018, Targeted delivery of antisense oligonucleotides to pancreatic β-cells, Sci Adv, 4, 3386, 10.1126/sciadv.aat3386 Satake, 2016, Novel targeted therapy for precursor B-cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate, Mol Med, 22, 632, 10.2119/molmed.2015.00210 Arnold, 2018, Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells, Molecular Therapy-Nucleic Acids, 11, 518, 10.1016/j.omtn.2018.04.004 Daraee, 2016, Application of liposomes in medicine and drug delivery, Artif Cells Nanomed Biotechnol, 44, 381, 10.3109/21691401.2014.953633 Gagliardi, 2021, The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery, Biomedicines, 9, 433, 10.3390/biomedicines9040433 Nag, 2013, Surface engineering of liposomes for stealth behavior, Pharmaceutics, 5, 542, 10.3390/pharmaceutics5040542 Magarkar, 2014, Cholesterol level affects surface charge of lipid membranes in saline solution, Sci Rep, 4, 5005, 10.1038/srep05005 Pagnan, 2000, Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects, J Natl Cancer Inst, 92, 253, 10.1093/jnci/92.3.253 Selvam, 1996, Inhibition of HIV replication by immunoliposomal antisense oligonucleotide, Antiviral Res, 33, 11, 10.1016/S0166-3542(96)00993-X Zelphati, 1994, Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms, Nucleic Acids Res, 22, 4307, 10.1093/nar/22.20.4307 Zelphati, 1994, Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes, Antiviral Res, 25, 13, 10.1016/0166-3542(94)90090-6 Zelphati, 1993, Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes, Antisense Res Dev, 3, 323, 10.1089/ard.1993.3.323 Leonetti, 1990, Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication, Proc Natl Acad Sci, 87, 2448, 10.1073/pnas.87.7.2448 Sicard, 2020, Enhanced antisense oligonucleotide delivery using cationic liposomes grafted with trastuzumab: A proof-of-concept study in prostate cancer, Pharmaceutics, 12, 1166, 10.3390/pharmaceutics12121166 Hughes, 2000, In vitro transport and delivery of antisense oligonucleotides, Vol. 313, 342 Lysik, 2003, Innovations in oligonucleotide drug delivery, J Pharm Sci, 92, 1559, 10.1002/jps.10399 Lee, 2017, Stimuli-responsive liposomes for drug delivery, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 9, e1450, 10.1002/wnan.1450 Skalko-Basnet, 2000, Delivery of antisense oligonucleotides to neuroblastoma cells, Neuroreport, 11, 3117, 10.1097/00001756-200009280-00016 Skalko-Basnet, 2002, Uptake of liposomally entrapped fluorescent antisense oligonucleotides in NG108-15 cells: conventional versus pH-sensitive, Biological and Pharmaceutical Bulletin, 25, 1583, 10.1248/bpb.25.1583 Fattal, 2004, Smart delivery of antisense oligonucleotides by anionic pH-sensitive liposomes, Adv Drug Deliv Rev, 56, 931, 10.1016/j.addr.2003.10.037 Düzgünes, 2001, Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes, Nucleosides Nucleotides Nucleic Acids, 20, 515, 10.1081/NCN-100002327 Lubrich, 2000, Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes, Eur J Biochem, 267, 2432, 10.1046/j.1432-1327.2000.01255.x Ponnappa, 2001, In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats, J Pharmacol Exp Ther, 297, 1129 Ashizawa, 2015, Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01, Expert Opin Drug Deliv, 12, 1107, 10.1517/17425247.2015.996545 Morris, 1997, A new peptide vector for efficient delivery of oligonucleotides into mammalian cells, Nucleic Acids Res, 25, 2730, 10.1093/nar/25.14.2730 Mäe, 2009, A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy, J Control Release, 134, 221, 10.1016/j.jconrel.2008.11.025 Järver, 2015, Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides, Nucleic Acid Ther, 25, 65, 10.1089/nat.2014.0511 Sully, 2016, Antisense antimicrobial therapeutics, Curr Opin Microbiol, 33, 47, 10.1016/j.mib.2016.05.017 Rahman, 1991, Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs, Antisense Res Dev, 1, 319, 10.1089/ard.1991.1.319 Bai, 2010, Antisense antibiotics: a brief review of novel target discovery and delivery, Curr Drug Discov Technol, 7, 76, 10.2174/157016310793180594 Rasmussen, 2007, Hitting bacteria at the heart of the central dogma: sequence-specific inhibition, Microb Cell Fact, 6, 1, 10.1186/1475-2859-6-24 Hegarty, 2018, Advances in therapeutic bacterial antisense biotechnology, Appl Microbiol Biotechnol, 102, 1055, 10.1007/s00253-017-8671-0 Geller, 2005, Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis, J Antimicrob Chemother, 55, 983, 10.1093/jac/dki129 Deere, 2005, Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli, Antimicrob Agents Chemother, 49, 249, 10.1128/AAC.49.1.249-255.2005 Mellbye, 2009, Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo, Antimicrob Agents Chemother, 53, 525, 10.1128/AAC.00917-08 Mellbye, 2010, Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo, J Antimicrob Chemother, 65, 98, 10.1093/jac/dkp392 Ayhan, 2016, Sequence-specific targeting of bacterial resistance genes increases antibiotic efficacy, PLoS Biol, 14, e1002552, 10.1371/journal.pbio.1002552 Sully, 2017, Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo, J Antimicrob Chemother, 72, 782 Good, 1998, Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA, Nat Biotechnol, 16, 355, 10.1038/nbt0498-355 Dryselius, 2003, The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli, Oligonucleotides, 13, 427, 10.1089/154545703322860753 Tan, 2005, Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection, Antimicrob Agents Chemother, 49, 3203, 10.1128/AAC.49.8.3203-3207.2005 Nekhotiaeva, 2004, Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids, Mol Ther, 10, 652, 10.1016/j.ymthe.2004.07.006 Sawyer, 2013, A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model, Int J Pharm, 453, 651, 10.1016/j.ijpharm.2013.05.041 Liang, 2015, Inhibiting the growth of methicillin-resistant Staphylococcus aureus in vitro with antisense peptide nucleic acid conjugates targeting the ftsZ gene, Int J Infect Dis, 30, 1, 10.1016/j.ijid.2014.09.015 Goh, 2015, Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro, BMC Microbiol, 15, 1, 10.1186/s12866-015-0599-x Meng, 2009, Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA, Antimicrob Agents Chemother, 53, 2871, 10.1128/AAC.01542-08 Meng, 2015, Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide, J Antibiot, 68, 158, 10.1038/ja.2014.132 Meng, 2015, Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor, Antimicrob Agents Chemother, 59, 914, 10.1128/AAC.03781-14 Wang, 2010, oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides, FEMS Immunol Med Microbiol, 60, 275, 10.1111/j.1574-695X.2010.00742.x Hu, 2011, Inhibition of biofilm formation by the antisense peptide nucleic acids targeted at the motA gene in Pseudomonas aeruginosa PAO1 strain, World J Microbiol Biotechnol, 27, 1981, 10.1007/s11274-011-0658-x Howard, 2017, Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers, Antimicrob Agents Chemother, 61, 10, 10.1128/AAC.01938-16 Geller, 2013, Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo, J Infect Dis, 208, 1553, 10.1093/infdis/jit460 Lopez, 2015, Inhibition of AAC (6′)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2′, 4′-bridged nucleic acid-NC-DNA hybrid oligomer, Antimicrob Agents Chemother, 59, 5798, 10.1128/AAC.01304-15 Harth, 2000, Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication, Proc Natl Acad Sci, 97, 418, 10.1073/pnas.97.1.418 Harth, 2002, Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology, Proc Natl Acad Sci, 99, 15614, 10.1073/pnas.242612299 Harth, 2007, Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis, Proc Natl Acad Sci, 104, 7199, 10.1073/pnas.0701725104 Kulyté, 2005, Inhibition of Mycobacterium smegmatis gene expression and growth using antisense peptide nucleic acids, Microbial Physiology, 9, 101, 10.1159/000088840 Skvortsova, 2019, A new antisense phosphoryl guanidine oligo-2′-O-methylribonucleotide penetrates into intracellular mycobacteria and suppresses target gene expression, Front Pharmacol, 10, 1049, 10.3389/fphar.2019.01049 Jeon, 2009, Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter, J Antimicrob Chemother, 63, 946, 10.1093/jac/dkp067 Oh, 2014, Target optimization for peptide nucleic acid (PNA)-mediated antisense inhibition of the CmeABC multidrug efflux pump in Campylobacter jejuni, Journal of Antimicrobial, Chemotherapy69.2, 946 Rajasekaran, 2013, Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages, Int J Antimicrob Agents, 41, 358, 10.1016/j.ijantimicag.2012.11.017 Kurupati, 2007, Inhibition of gene expression and growth by antisense peptide nucleic acids in a multiresistant β-lactamase-producing Klebsiella pneumoniae strain, Antimicrob Agents Chemother, 51, 805, 10.1128/AAC.00709-06 Kalesinskas, 2015, Streptococcus mutans biofilm inhibition using antisense oligonucleotide to glucosyltransferases B and C, Acta medica Lituanica, 22, 85, 10.6001/actamedica.v22i2.3123 Patenge, 2013, Inhibition of growth and gene expression by PNA-peptide conjugates in Streptococcus pyogenes, Molecular Therapy-Nucleic Acids, 2, 10.1038/mtna.2013.62 Otsuka, 2016, Antimicrobial activity of antisense peptide–peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms, J Antimicrob Chemother, 72, 137, 10.1093/jac/dkw384 Mitev, 2009, Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer, Antimicrob Agents Chemother, 53, 3700, 10.1128/AAC.00099-09